Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Magnetic Resonance Imaging-Based Prediction of Prostate Cancer Risk-Reply.

Mehralivand S, Shih J, Turkbey B.

JAMA Oncol. 2018 Nov 1;4(11):1625. doi: 10.1001/jamaoncol.2018.4234. No abstract available.

PMID:
30326079
2.

Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.

Radtke JP, Wiesenfarth M, Kesch C, Freitag MT, Alt CD, Celik K, Distler F, Roth W, Wieczorek K, Stock C, Duensing S, Roethke MC, Teber D, Schlemmer HP, Hohenfellner M, Bonekamp D, Hadaschik BA.

Eur Urol. 2017 Dec;72(6):888-896. doi: 10.1016/j.eururo.2017.03.039. Epub 2017 Apr 8.

PMID:
28400169
3.

Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.

Alberts AR, Schoots IG, Bokhorst LP, van Leenders GJ, Bangma CH, Roobol MJ.

Eur Urol. 2016 Jun;69(6):1129-34. doi: 10.1016/j.eururo.2015.11.018. Epub 2015 Dec 2.

PMID:
26651990
4.

Impact of Lesion Visibility on Transrectal Ultrasound on the Prediction of Clinically Significant Prostate Cancer (Gleason Score 3 + 4 or Greater) with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Biopsy.

Garcia-Reyes K, Nguyen HG, Zagoria RJ, Shinohara K, Carroll PR, Behr SC, Westphalen AC.

J Urol. 2018 Mar;199(3):699-705. doi: 10.1016/j.juro.2017.09.075. Epub 2017 Sep 20.

PMID:
28941918
5.

Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.

Meng X, Rosenkrantz AB, Mendhiratta N, Fenstermaker M, Huang R, Wysock JS, Bjurlin MA, Marshall S, Deng FM, Zhou M, Melamed J, Huang WC, Lepor H, Taneja SS.

Eur Urol. 2016 Mar;69(3):512-7. doi: 10.1016/j.eururo.2015.06.005. Epub 2015 Jun 22.

6.

Magnetic resonance imaging-directed transperineal limited-mapping prostatic biopsies to diagnose prostate cancer: a Scottish experience.

Mukherjee A, Morton S, Fraser S, Salmond J, Baxter G, Leung HY.

Scott Med J. 2014 Nov;59(4):204-8. doi: 10.1177/0036933014556197. Epub 2014 Oct 14.

PMID:
25314954
7.

Imaging low-risk prostate cancer.

Shukla-Dave A, Hricak H, Scardino PT.

Curr Opin Urol. 2008 Jan;18(1):78-86. Review.

PMID:
18090495
8.

Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer.

Shukla-Dave A, Hricak H, Akin O, Yu C, Zakian KL, Udo K, Scardino PT, Eastham J, Kattan MW.

BJU Int. 2012 May;109(9):1315-22. doi: 10.1111/j.1464-410X.2011.10612.x. Epub 2011 Sep 20.

9.

Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment.

Bjurlin MA, Meng X, Le Nobin J, Wysock JS, Lepor H, Rosenkrantz AB, Taneja SS.

J Urol. 2014 Sep;192(3):648-58. doi: 10.1016/j.juro.2014.03.117. Epub 2014 Apr 21. Review.

10.

Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer.

Numao N, Yoshida S, Komai Y, Ishii C, Kagawa M, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Koga F, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K.

J Urol. 2013 Aug;190(2):502-8. doi: 10.1016/j.juro.2013.02.3197. Epub 2013 Mar 7.

PMID:
23473904
11.

Tumor lesion diameter on diffusion weighted magnetic resonance imaging could help predict insignificant prostate cancer in patients eligible for active surveillance: preliminary analysis.

Lee DH, Koo KC, Lee SH, Rha KH, Choi YD, Hong SJ, Chung BH.

J Urol. 2013 Oct;190(4):1213-7. doi: 10.1016/j.juro.2013.03.127. Epub 2013 May 28.

PMID:
23727188
12.

Ability of preoperative 3.0-Tesla magnetic resonance imaging to predict the absence of side-specific extracapsular extension of prostate cancer.

Hara T, Nakanishi H, Nakagawa T, Komiyama M, Kawahara T, Manabe T, Miyake M, Arai E, Kanai Y, Fujimoto H.

Int J Urol. 2013 Oct;20(10):993-9. doi: 10.1111/iju.12091. Epub 2013 Jan 29.

13.

Clinically low-risk prostate cancer: evaluation with transrectal doppler ultrasound and functional magnetic resonance imaging.

Novis MI, Baroni RH, Cerri LM, Mattedi RL, Buchpiguel CA.

Clinics (Sao Paulo). 2011;66(1):27-34.

14.

Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer.

Vargas HA, Akin O, Afaq A, Goldman D, Zheng J, Moskowitz CS, Shukla-Dave A, Eastham J, Scardino P, Hricak H.

J Urol. 2012 Nov;188(5):1732-8. doi: 10.1016/j.juro.2012.07.024. Epub 2012 Sep 25.

15.

The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction.

Distler FA, Radtke JP, Bonekamp D, Kesch C, Schlemmer HP, Wieczorek K, Kirchner M, Pahernik S, Hohenfellner M, Hadaschik BA.

J Urol. 2017 Sep;198(3):575-582. doi: 10.1016/j.juro.2017.03.130. Epub 2017 Mar 31.

PMID:
28373135
16.

Magnetic Resonance Imaging-Based Prostate-Specific Antigen Density for Prediction of Gleason Score Upgrade in Patients With Low-Risk Prostate Cancer on Initial Biopsy.

Sim KC, Sung DJ, Kang KW, Yang KS, Han NY, Park BJ, Kim MJ, Cho SB.

J Comput Assist Tomogr. 2017 Sep/Oct;41(5):731-736. doi: 10.1097/RCT.0000000000000579.

PMID:
28914751
17.

D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging.

Rastinehad AR, Baccala AA Jr, Chung PH, Proano JM, Kruecker J, Xu S, Locklin JK, Turkbey B, Shih J, Bratslavsky G, Linehan WM, Glossop ND, Yan P, Kadoury S, Choyke PL, Wood BJ, Pinto PA.

J Urol. 2011 Mar;185(3):815-20. doi: 10.1016/j.juro.2010.10.076. Epub 2011 Jan 15.

18.

Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies.

Ouzzane A, Renard-Penna R, Marliere F, Mozer P, Olivier J, Barkatz J, Puech P, Villers A.

J Urol. 2015 Aug;194(2):350-6. doi: 10.1016/j.juro.2015.02.2938. Epub 2015 Mar 5.

PMID:
25747105
19.

AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer.

Fulgham PF, Rukstalis DB, Turkbey IB, Rubenstein JN, Taneja S, Carroll PR, Pinto PA, Bjurlin MA, Eggener S.

J Urol. 2017 Oct;198(4):832-838. doi: 10.1016/j.juro.2017.04.101. Epub 2017 May 5.

PMID:
28483574
20.

Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy.

Muthigi A, George AK, Sidana A, Kongnyuy M, Simon R, Moreno V, Merino MJ, Choyke PL, Turkbey B, Wood BJ, Pinto PA.

J Urol. 2017 Feb;197(2):327-334. doi: 10.1016/j.juro.2016.08.097. Epub 2016 Aug 28.

Supplemental Content

Support Center